

RESEARCH ARTICLE

Incidence of venous thromboembolism and bleeding in patients with malignant central nervous system neoplasm: Systematic review and meta-analysis

Viviane Cordeiro Veiga^{1☯*}, Stela Verzinhasse Peres^{1☯}, Thatiane L. V. D. P. Ostolin^{1☯}, Flavia Regina Moraes^{1☯}, Talita Rantin Belucci^{1‡}, Carlos Afonso Clara^{2‡}, Alexandre Biasi Cavalcanti^{3‡}, Feres Eduardo Aparecido Chaddad-Neto^{4‡}, Gabriel N. de Rezende Batistella^{3‡}, Iuri Santana Neville^{5‡}, Alex M. Baeta^{1‡}, Camilla Akemi Felizardo Yamada^{1☯}, on behalf of the TROMBOGLIO Study Group[¶]


1 BP–A Beneficência Portuguesa de São Paulo, São Paulo, Brasil, **2** Hospital do Câncer de Barretos, São Paulo, Brasil, **3** HCor–Research Institute, São Paulo, Brasil, **4** Universidade Federal de São Paulo, São Paulo, Brasil, **5** Instituto do Câncer de São Paulo, São Paulo, Brasil

☯ These authors contributed equally to this work.

‡ TRB, CAC, ABC, ISN and AMB also contributed equally to this work.

¶ Membership of the TROMBOGLIO Study Group is provided in the Acknowledgments.

* viviane.veiga@bp.org.br



OPEN ACCESS

Citation: Veiga VC, Peres SV, Ostolin TLVDP, Moraes FR, Belucci TR, Clara CA, et al. (2024) Incidence of venous thromboembolism and bleeding in patients with malignant central nervous system neoplasm: Systematic review and meta-analysis. PLoS ONE 19(6): e0304682. <https://doi.org/10.1371/journal.pone.0304682>

Editor: Omar A. Almohammed, King Saud University, SAUDI ARABIA

Received: November 29, 2023

Accepted: May 16, 2024

Published: June 20, 2024

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0304682>

Copyright: © 2024 Veiga et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are in the manuscript and its [supporting information files](#).

Abstract

Purpose

Central nervous system (CNS) malignant neoplasms may lead to venous thromboembolism (VTE) and bleeding, which result in rehospitalization, morbidity and mortality. We aimed to assess the incidence of VTE and bleeding in this population. Methods: This systematic review and meta-analysis (PROSPERO CRD42023423949) were based on a standardized search of PubMed, Virtual Health Library and Cochrane (n = 1653) in July 2023. After duplicate removal, data screening and collection were conducted by independent reviewers. The combined rates and 95% confidence intervals for the incidence of VTE and bleeding were calculated using the random effects model with double arcsine transformation. Subgroup analyses were performed based on sex, age, income, and type of tumor. Heterogeneity was calculated using Cochran's Q test and I² statistics. Egger's test and funnel graphs were used to assess publication bias. Results: Only 36 studies were included, mainly retrospective cohorts (n = 30, 83.3%) from North America (n = 20). Most studies included were published in high-income countries. The sample size of studies varied between 34 and 21,384 adult patients, mostly based on gliomas (n = 30,045). For overall malignant primary CNS neoplasm, the pooled incidence was 13.68% (95%CI 9.79; 18.79) and 11.60% (95%CI 6.16; 18.41) for VTE and bleeding, respectively. The subgroup with elderly people aged 60 or over had the highest incidence of VTE (32.27% - 95%CI 14.40;53.31). The studies presented few biases, being mostly high quality. Despite some variability among the studies, we observed consistent results by performing sensitivity analysis, which highlight the robustness of our findings. Conclusions: Our study showed variability in the pooled incidence for

Funding: VCV, SVP, TLVDPO, FRM, TRB, CAC, ABC, FECN, GNRB, ISNR, AMB and CAFY. The study is being developed at BP - A Hospital Beneficência Portuguesa of São Paulo with support of Brazilian Ministry of Health, project number NUP 25000.1121542022-98 PROADI / SUS. URL: <https://www.in.gov.br/web/dou/-/extrato-de-ajuste-520387500> The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Competing interests: The authors have declared that no competing interests exist.

both overall events and subgroup analyses. It was highlighted that individuals over 60 years old or diagnosed with GBM had a higher pooled incidence of VTE among those with overall CNS malignancies. It is important to note that the results of this meta-analysis refer mainly to studies carried out in high-income countries. This highlights the need for additional research in Latin America, and low- and middle-income countries.

Introduction

Central nervous system (CNS) tumors are among the ten most common types of cancer in middle-aged adults, especially in women [1]. Malignant primary CNS tumors represent 1 to 2% of all cancers in adults [2], with glioblastoma multiforme (GBM) accounting for 49% of this group [3]. Global demographic and epidemiological trends indicate an increase in the incidence in coming decades [4], especially in low and medium-income countries [5]. The main risk factors are related to family history, age, male sex, human immunodeficiency virus (HIV) infections, ionizing radiation exposure, pesticides, and cyclic aromatic hydrocarbons [6].

Among the outcomes related to primary CNS tumors, venous thromboembolism (VTE) is one of the main causes of rehospitalization and increased morbidity and mortality [4, 7]. Among tumors, CNS neoplasm is related to the greater incidence of annual thrombotic events (200 per 1,000 person-years) [8], most occurring from three to six months after diagnosis, associated with early mortality. The etiology of these events is multifactorial and includes venous stasis, direct activation of the coagulation cascade due to tissue damage, as well as pro-coagulation effects specific to the tumor [9]. Other risk factors include advanced age, tumor size, steroid use, chemotherapy, and radiotherapy [9]. Among CNS tumors, GBM with wild type isocitrate dehydrogenase (IDH) has a poorer prognosis and higher incidence of thrombotic events, estimated at approximately 20–30% per year [9].

The increased risk of venous thromboembolism (VTE) in cancer patients is particularly notable, and in neurosurgery, the introduction of pharmacological prophylaxis is well established in the literature and should be instituted 24 hours after the procedure [10, 11]. Given the substantial pathogenic propensity inherent to central nervous system (CNS) neoplasms, triggering thrombotic events such as ischemic stroke, myocardial infarction, peripheral arterial disease, and deep vein thrombosis (DVT), anticoagulants are a preventive measure against these potential risks. Conversely, the occurrence of minor or major hemorrhagic events in internal organs is closely connected to the underlying pathological condition of the disease and may be exacerbated by the prophylactic or therapeutic administration of anticoagulants. In this clinical milieu, it is imperative to meticulously assess and balance the inherent risk associated with these two complications. The aim of this systematic review and meta-analysis was to assess the incidence of VTE and bleeding in adults diagnosed with malignant primary CNS neoplasm.

Materials and methods

This systematic review and meta-analysis were developed and conducted according to the recommendations in the manual of the Joanna Briggs Institute, and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [12, 13]. The protocol of this review was previously developed and registered on the International Prospective Register of Systematic Reviews Platform (PROSPERO CRD42023423949).

The scope of this review was established based on Condition, Context and Population (CoCoPop), i.e., Condition (VTE and bleeding), Context (post-diagnosis or postoperative, regardless active treatment and prophylaxis), and Population (adults diagnosed with malignant primary CNS neoplasm).

They used the following definition for VTE: any symptomatic or incidental event involving the upper or lower limbs, confirmed by imaging examinations such as venous Doppler ultrasound and/or computerized tomography of the lungs, lung scintigraphy, and angiography [7]. Arterial thromboembolic events and splenic vein thrombosis were excluded. Bleeding was defined as a fatal or symptomatic hemorrhage in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, pericardial, non-operated or intramuscular joint with compartment syndrome) [14].

Eligibility criteria and outcomes

The following were considered eligible: (1) cohort studies (prospective and retrospective), case-control nested cohort studies, and cohort nested case-control studies that (2) assessed the presence of VTE and bleeding in (3) patients with malignant primary CNS neoplasm. The studies were deemed eligible when presenting, at least, a numerator and denominator for the total sample to calculate the event of interest. Review and metaanalysis studies, letters to the editor, opinion articles, comments, short communications, ecological studies, and abstracts published in the annals of scientific events were not included. Studies that investigated metastatic tumors, CNS lymphoma and meningioma below grade 3 were also excluded.

The study search was limited to the period between 2013 and 2023. The period was limited to the largest number of publications on the topic and with more homogeneous patient selection criteria. Only studies published in English, Portuguese and Spanish were analyzed given the familiarity of the reviewers with these languages.

Search strategy and screening

Potentially eligible citations were identified through a search of PubMed, Virtual Health Library and Cochrane databases. Two reviewers (SVP, TLVDPO) developed the search strategy based on the Health Science Descriptors/Medical Subject Headings (DeCS/MeSH), combining descriptors, entry terms, and free vocabulary, if needed. Specialists in the area, physicians with a specialization in intensive care and neuro-oncologists, and oncology nurses were consulted to ensure the comprehensiveness and sensitivity of the search (VCV, CAFY, and FRdM, respectively). Although standardized, the search strategy underwent minimum adjustments (i.e., minor differences in filters, for instance, using Full text, Case Reports, and Observational Studies, in the last 10 years, in English, Portuguese, Spanish, in Adults 19 years or older. Excluded were preprints as filters for PubMed, while `fulltext, type_of_study:"observational_studies" OR "incidence_studies" OR "prevalence_studies", la:"en" OR "es" OR "pt", and year cluster for BVS`) according to the database investigated as shown in the supplementary file (S1 Table. Search strategy according to electronic databases). However, the search focused on MeSH terms for all databases since PubMed, BVS and Cochrane considered them controlled vocabulary. The search was structured around three main concepts (central nervous system tumor, thrombosis, and bleeding) and described according to the databases.

The search results were saved in txt, ris or csv formats. Then, the files were saved in Rayyan® software to screening and eligibility. A priori, possible duplicate citations were identified and manually verified by the reviewers. Two independent blind reviewers (SVP and TLVDPO) analyzed the titles and abstracts. In case of disagreement, a third reviewer (FRdM) analyzed the studies. After study selection, eligibility was determined by retrieving the studies,

and three reviewers (SVP, FRdM and TLVDPO) analyzed the full texts, under the supervision and guidance of specialists from the area (VCV, CAFY). The reasons for exclusion were listed in the two stages, according to the eligibility criteria established (Study type, Population, Outcome, Language, Unavailable and/or Not retrieved).

Data collection and synthesis

Specialists (VCV, CAFY, FRdM) were consulted to ensure study eligibility. Two independent blind reviewers (SVP, TLVDPO) extracted the data using a previously developed standardized spreadsheet. The extracted data were divided into (1) overall study characterization (citation, year and country of publication, study design, study period, follow-up) and (2) participants and main outcomes (total sample, sex, age and/or age range, tumor type and/or site, treatment, and health-related events). This information was extracted using REDCap®, which was previously structured. Both screening and data extraction were conducted in accordance with the guide produced during development of the study protocol. In addition, funding sources or possible conflicts of interest were registered, when available in the studies included. The main findings were presented in tables and figures accompanied by a narrative synthesis.

Risk of bias

The studies were critically assessed by two independent reviewers (SVP, TLVDPO) using the Prevalence Critical Appraisal Tool proposed by the Joanna Briggs Institute [12]. A third reviewer assessed the studies in case of any disagreement. The studies were evaluated based on the number of positive responses (i.e., No, Unclear and Yes) and overall analysis (i.e., Include, Exclude, or Seek more information).

Statistical analysis

Descriptive analysis of the data was carried out using absolute and relative frequencies. Meta-analysis results were developed independently for VTE and bleeding as outcomes. The RStudio program (version 4.5, metaprop package) was used for data analysis. The combined rates and 95% confidence intervals (CI) for the incidence of VTE and bleeding were calculated using the random (DerSimonian-Laird) effects model with double arcsine transformation. Subgroup analyses were performed based on sex (e.g., female and male), age (≥ 60 years old), income (high income and upper-middle income countries), and type of tumor (overall CNS and GBM). The random effects model was used rather than its fixed effects counterpart due to the heterogeneity of the studies. Heterogeneity was calculated using Cochran's Q test and I^2 statistics (i.e., quantifying the proportion of total variation between the studies). The I^2 values were classified as insignificant (0–25%), low (26–50%), moderate (51–75%) and high heterogeneity ($> 75\%$). Egger's test and funnel graphs were used to assess publication bias. Significance was set at 5% for all the tests. Finally, sensitivity analyses were performed for subgroups, specifically focusing on the overall CNS and GBM. Each analysis was reiterated by excluding studies with a high risk of bias and outliers' values.

Protocol deviations

Some protocol deviations must be addressed. The protocol did not contemplate the use of filters in the databases and did not include publication date restrictions. However, given the broaden scope adopted, mainly regarding of tumor types and events of interest, the use of filters favored study screening. Thus, the filters used were described in the search strategy according to the databases, including the data of publication (less than or equal to 10 years),

language (Portuguese, English, Spanish), study type/design and others (i.e., exclusion of pre-prints, adults over 19 years of age and full texts), when available. Descriptors and entry terms for study type/design and analysis of interest in this review were also used (e.g., prevalence, incidence, hazard ratio, odds ratio). In addition, we only searched in PubMed, BVS and Cochrane. Other databases included in our protocol, such as Embase, contain a high rate of duplicate citations with PubMed and Cochrane. We prioritized BVS because it includes Latin American and Caribbean publications. When considering medRxiv, Google Scholar and OpenGrey, the broad scope of the search strategy required a focus on better-quality evidence in order to ensure data reliability. The subgroup analysis was adjusted to better describe the findings. Based on the data availability in the evaluated studies, subgroup analysis was carried out according to sex and age. Even though it was not considered a priori, a sensitivity analysis was conducted by removing the outliers from the sample, which could be related to the study design and their methodological quality.

Results

Database searches were carried from June to July 2023. A total of 1653 potentially eligible citations were identified (Fig 1). Possible duplicate studies were identified by the Rayyan® software, but reviewers verified one by one and resolved manually. A priori, 1589 titles and abstracts were screened. Among the excluded studies, the primarily reason was the population. The studies excluded were listed with the reasons. Studies that included different cancer types and sites were not considered eligible. Only 36 studies were eligible and included in the present review [15–50], 28 showed information for VTE and 18 for bleeding. The study screening process was summarized in a flowchart, as can be seen in Fig 1.

Overall, the studies were retrospective cohorts ($n = 30$, 83.3%) published in North America ($n = 20$), Europe ($n = 9$) and East Asia ($n = 7$). The United States ($n = 18$, 50%), China ($n = 5$, 13.8%) and Germany ($n = 4$, 11.1%) were the countries that published most of the included studies. Most studies included were published in high-income countries, except for 5 (13.8%) from countries classified as upper-middle income (Table 1). Neither lower-middle or low income appeared among the countries of publication from the analyzed studies. Among the studies examined in Table 1, noteworthy findings pertain to the risk factors identified in both univariate and multivariate analyses. Across these studies, advanced age was correlated with the outcomes under investigation in this meta-analysis. Performance status was similarly highlighted in three studies, while a history of VTE was documented in two. Additional studies were specifically chosen to illustrate outcome incidence, although the primary focus on risk factors, along with their corresponding adjustment variables, was directed toward the outcomes of death or recurrence.

Participants

The sample size of studies varied between 23 and 21,384 adult patients. In studies that provided incidence values by sex ($n = 9$), 62.7% of participants were men ($n = 1,779$). Only three studies presented data on patients aged 60 years or older (28,31–32), totaling 163 patients with VTE out of 446 patients with CNS (36.5%).

Of the 36 studies included, 20 were based on gliomas ($n = 30,045$). It is noteworthy the study by Missios et al. [37] that analyzed a sample of 21,384 gliomas. Regarding patients diagnosed with GBM, 19 studies were identified, with a total sample size of 8,390.

When taken into account the outcomes, we highlighted whether the studies analyzed only one of the outcomes or both of them. The number of events for each outcome can be seen in Table 1 that also includes a general patients' characteristics (type of cancer, total number of




Fig 1. Flowchart showing selection and inclusion of observational studies in systematic review and meta-analysis.

<https://doi.org/10.1371/journal.pone.0304682.g001>

patients, proportion of participants from sex and age) and the study period. Unfortunately, other cancer- and patient-related aspects were not included due to a heterogeneous patients' characterization among the studies.

Incidence of VTE and bleeding

Our findings were described separately for VTE and bleeding. In general, the pooled incidence ranged from 1.48 to 50.51% for VTE and from 1.69 to 45.86% for bleeding.

For overall malignant primary CNS neoplasm, the pooled incidence VTE was 13.68% (95% CI 9.79; 18.79). Similarly, the pooled incidence for bleeding was 11.60% (95%CI 6.16; 18.41).

To assess outcomes in specific subpopulations within the set of studies, subgroup analysis was performed. The studies were grouped based on specific characteristics, such as sex, age group, type of tumor, and country income. When only GBM were considered, the pooled incidence was 16.10% (95%CI 10.52; 22.57) for VTE and 8.29% (95%CI 3.26; 15.24) for bleeding. Except for GBM, the others subgroup analyzes were summarized in Table 2 (Fig 2). The forest plots for subgroup analysis can be found in the supplementary material (S1A-S1F Fig in S1 File).

Table 1. Patients' characteristics of the included studies.

Author	Type of cancer	Sample Size†	Sex (M/F)	Age	VTE	Bleeding	Study period	Cohort	Variable as Risk factors
Auer et al., 2017	GBM	82	56/26	56.5 (28–78)	NR	3	2006–2014	R	No evidence was observed
Barbaro et al., 2022	HGG	152	96/57	61.5 (21–87)	4	5	2014–2019	R	NA (death as outcome)
Bruhns et al., 2018	GBM	71	45/26	59	NR	19	2011–2016	R	NA (death as outcome)
Carney et al., 2018	Glioma, Astrocytoma and Ependymoma	67	41/26	56 (26–89)	NR	9	2011–2018	R	No evidence was observed
Diaz et al., 2021	Glioma	480	Grade II: 49/75 Grade III: 59/50 Grade IV: 194/140	Grade II: 42.7 (32.4–53.2) Grade III: 50.0 (35.2–59.6) Grade IV: 61.3 (52.6–70.4)	Grade II: 12 Grade III: 10 Grade IV: 103	NR	2005–2017	R	IDH wild-type
Ebeling et al., 2018	GBM	153	Non-IPC: 44/34 IPC: 47/28	Non-IPC: 50.7 (26–75) IPC: 53.1 (24–76)	12	NR	2009–2015	R	No evidence was observed
Eisele et al., 2021	GBM	414	Non-VTE: 216/133 VTE: 45/20	Non-VTE: 63.0 (18–90) VTE: 59.7 (37–83)	65	14	2005–2014	R	For VTE: History of a prior VTE
Ening et al., 2014	GBM	233	Without complication: 39/35 With complication: 78/81	Without complication: 57.9 With complication: 63.9	NR	7	2006–2011	R	Older Age, Radiotherapy, Chemotherapy, performance status, comorbidities, eloquent tumor location,
Fisher et al., 2014	GBM and Other CNS malignancy	2,424	NR	NR	670	290	1993–2006	R*	NA (comorbidities as outcome)
Helmi et al., 2019	GBM	163	No DVST: 98/53 DVST: 9/3	No DVST: 54.0 ± 10.3 DVST: 51.6 ± 9.2	12	NR	2009–2015	R	Tumor invasion of dural sinuses and greater T1/fluid-attenuated inversion recovery ratios
Huang et al., 2022	GBM	131	80/51	63 (58–67)	48	NR	2017–2019	P	Performance status, D-dimer and EGFR amplification Status
Jo et al., 2022	HGG	220	120/100	LMWH: 58 (21–84) Non-AC with VTE: 61 (41–85) Non-VTE: 59 (21–85)	22	43	2005–2016	R	Bleeding as outcome and VTE as independent variable. No evidence was observed
Kaptein et al., 2021	GBM	967	580/387	63 (12)	101	126	2004–2020	R	For VTE: Older age, type of surgery, and performance status. For bleeding: VTE.
Kaye et al., 2023	GBM	293	EGFR Non-Amplified: EGFR-Amplified:	EGFR Non-Amplified: 64 (17–95) EGFR-Amplified: 64 (35–84)	148	NR	2015–2021	R	EGFR (not-amplified for subgroups age > 60)
Khoury et al., 2016	GBM	523	107/66	65 (34–89)	173	17	2007–2013	R	No evidence was observed
Lee et al., 2019	HGG	918	VTE: 66/33 Control: 537/282	VTE: 56.6 (10.4) Control: 56.3 (8.1)	99	NR	2009–2015	R*	No evidence was observed
Lee et al., 2022	HGG	203	115/88	54 (19–76)	3	5	2015–2020	R	NA (death and progression-free as outcome)

(Continued)

Table 1. (Continued)

Author	Type of cancer	Sample Size†	Sex (M/F)	Age	VTE	Bleeding	Study period	Cohort	Variable as Risk factors
Lim et al., 2018	GBM	115	75/40	57 (23–83)	23	NR	2010–2014	R	NA (death as outcome)
Liu et al., 2019	GBM	404	257/147	59 (20–91)	14	14	2010–2014	R	For VTE: Preoperative status performance; For bleeding: Postoperative Arterial pressure fluctuation
Liu et al., 2023	Gliomas, Glio-neuronal and neuronal tumors, Anaplastic meningioma/ependymomas	456	284/172	56 (46–66)	84	NR	2018–2021	R	Age $\geq$ 60, preoperative abnormal APTT, operation duration longer than 5 h, admission to ICU, intraoperative plasma transfusion
Mantia et al., 2017	GBM, Anaplastic oligodendroglioma, Anaplastic astrocytoma	133	Enoxaparin: 33/17 Control: 48/45	Enoxaparin: 62 (26–89) Control: 61 (24–82)	NR	61	2000–2016	R ^y	Platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic blood pressure, stroke
McGahan et al., 2017	GBM	39	Gbm with hemorrhage: 8/9 GBM without hemorrhage: 12/10	GBM with hemorrhage: 68.2 (30–71) GBM without hemorrhage: 60.6 (35–84)	NR	17	2007–2013	R	higher IHC staining for CD34 and CD105.
Missios al., 2015	Glioma	21,384	8924/12260	53.99 $\pm$ 15.91	788	NR	2005–2011	R	Older Age, gender, West region hospitals, cardiovascular disease, coagulopathy, length of stay, seizures.
Nakano et al., 2018	LGG, HGG,	23	NR for specific subgroup	NR for specific subgroup	7	NR	2014–2017	R	Infection
Nazari et al., 2020	Glioma	193	121/72	55 (44–66)	26	NR	2003–2014	P	Circulating lymphocytes
Park et al., 2021	GBM, Anaplastic astrocytoma, Anaplastic oligoastrocytoma, Medulloblastoma	34	12/22	60.7 (55.3–66.1)	NR	9	1999–2021	R	No evidence was observed
Rahman et al., 2015	GBM	196	119/77	59 (23–90)	31	11	2006–2010	R	NA (death as outcome)
Rinaldo et al., 2019	Glial-based tumor	784	NR for specific subgroup	NR for specific subgroup	10	NR	2012–2017	R	For VTE: Age, History of VTE, Pre- or postop motor deficit, Postop intracranial hemorrhagic, Intubated $>$ 24 hrs/reintubated
Seidel et al., 2013	Glioma	3,889	NR	NR	143	123	2004–2010	P	No risk analysis
Senders et al., 2018	HGG	301	176/125	57.7 $\pm$ 13.2	20	9	2007–2013	R ^y	For VTE: immobility and high body mass index. For bleeding: prolonged thromboprophylaxis.
Shi et al., 2020	LGG, HGG, Glioneuronal	492	NR for specific subgroup	NR for specific subgroup	73	NR	2018–2019	R	Older age, BMI, preoperative APTT, D-dimer, tumor histology, and surgery duration
Streiff et al., 2015	HGG	107	52/55	57 (28–85)	26	NR	2005–2008	P	Patients without complete resection and high factor VIII activity
Thaler et al., 2013	Gliomas	82	NR for specific subgroup	NR for specific subgroup	13	NR	2003–2010	P	No evidence was observed

(Continued)

Table 1. (Continued)

Author	Type of cancer	Sample Size‡	Sex (M/F)	Age	VTE	Bleeding	Study period	Cohort	Variable as Risk factors
Unruh et al., 2016	Glioma	317	Discovery Cohort IDH1/2 Wild-type: 61/56 IDH1/2 Mutant: 27/25 Validation Cohort IDH1/2 Wild-type: 67/47 IDH1/2 Mutant: 20/14	Discovery Cohort IDH1/2 Wild-type: 60.6 ± 1.1 IDH1/2 Mutant: 39.4 ± 1.6 Validation Cohort IDH1/2 Wild-type: 64.4 ± 1.3 IDH1/2 Mutant: 46.0 ± 2.1	61	NR	2009–2014	P	IDH1 wild-type
Zhang et al., 2023	Glioma	435	Non-VTE: 204/150 VTE: 53/28	Non-VTE: 42 VTE: 55	81	NR	2012–2021	R	Age, operation time, systemic immune-inflammation index (SII) and hypertension.
Zhou et al., 2022	HGG	154	Recurrence: 38/27 Nonrecurrence: 54/35	Recurrence: 48.95 ± 13.00 Nonrecurrence: 49.10 ± 11.90	NR	48	2016–2021	R	NA (recurrence as outcome)

‡ values presented for valid malignancy; DVST: Dural Venous Sinus Thrombosis; DVT: Deep Vein Thrombosis; EGFR: Epidermal Growth Factor Receptor; F: Females; GBM: Glioblastoma Multiforme; HGG: High Grade Glioma; IDH: Isocitrate Dehydrogenase; LGG: Low Grade Glioma; LMWH: Low-molecular-weight heparin; M: Males; NA: Not applicable; NR: Not reported; P: Prospective; R: Retrospective; VTE: Venous Thromboembolism; * case-control nested cohort; ‡ cohort nested case-control.

<https://doi.org/10.1371/journal.pone.0304682.t001>

When considering upper-middle income countries, the pooled incidence of VTE was 12.68% (95% CI 3.43; 26.13) with an I^2 of 82.0%. This value indicated lower heterogeneity than found for overall analysis ($I^2 = 99\%$). We also highlighted the wider confidence interval in addition to the fact that this subgroup consisted of only three studies. Among these studies, none reported bleeding events. For high income countries, the pooled incidence for both outcomes did not vary when considering the confidence intervals and the heterogeneity values (as can be seen in Table 2).

Among the demographic characteristics analyzed, the subgroup with elderly people aged 60 or over had the highest incidence of VTE (32.27% - CI95% 14.40;53.31) as expectedly.

According to sex, we observed a decrease in heterogeneity that reached 88% for men and 81% for women with pooled incidence of 16.52% and 15.46% respectively.

Assessment of publication bias

In the visual analysis through the funnel plot, we observed the presence of asymmetry in the studies as can be seen in Fig 3, where studies with larger sample sizes cluster at the top but extend beyond the confidence interval. Egger's test was applied for analysis with ten or more studies due to methodological limitations.

In overall tumor analysis, the asymmetry was identified for VTE and bleeding ($p < 0.001$ and $p = 0.011$, respectively). Regarding high income countries subgroup, there was asymmetry for both VTE ($p = 0.001$) and bleeding ($p = 0.009$) (Table 2). Conversely, the studies on GBM tumors did not showed asymmetry in both analyzes for VTE ($p = 0.216$) and bleeding ($p = 0.303$). These analyzes can be found in Supporting information.

Table 2. Summary of VTE and bleeding pooled incidence according to overall and subgroup sample.

Number of studies (Figure)	Group	Events	Pooled Incidence (95%CI) [‡]	I ²	<i>t</i> ²	p [*]
28 studies (Fig 2A)	CNS	VTE	13.68 (9.79; 18.09)	99%	0.0249	<0.001
18 studies (Fig 2B)	CNS	Bleeding	11.60 (6.16; 18.41)	97%	0.0398	0.011
Number of studies (Figure)	Subgroup	Events	Pooled Incidence (95%CI) [‡]	I ²	<i>t</i> ²	p [*]
16 studies (Fig 2C)	GBM	VTE	16.10 (10.52; 22.57)	98%	0.0264	0.216
10 studies (Fig 2D)	GBM	Bleeding	8.29 (3.26; 15.24)	95%	0.0284	0.303
8 studies (S1a Fig in S1 File)	CNS Sex = male	VTE	16.52 (10.25; 23.89)	88%	0.0152	NA
8 studies (S1b Fig in S1 File)	CNS Sex = female	VTE	15.42 (9.41; 22.63)	81%	0.0137	NA
3 studies (S1c Fig in S1 File)	CNS Age ≥ 60	VTE	32.27 (14.40; 53.31)	95%	0.0355	NA
3 studies (S1d Fig in S1 File)	CNS Upper-middle income countries	VTE	12.68 (3.43; 26.13)	83%	0.0190	NA
25 studies (S1e Fig in S1 File)	CNS High income countries	VTE	13.28 (9.03; 18.19)	99%	0.0278	0.001
17 studies (S1d Fig in S1 File)	CNS High income countries	Bleeding	12.29 (6.50; 19.53)	97%	0.0405	0.009

[‡] Random effect model analysis

^{*} p value calculated by using Egger test, NA = Not applicable (Egger test was not conducted due to total number of studies minor than 10); CI: Confidence interval; CNS: central nervous system; GBM: glioblastoma multiforme; VTE: venous thromboembolism.

<https://doi.org/10.1371/journal.pone.0304682.t002>

Risk of bias


The studies were assessed by two reviewers. The results were presented by study and general summary (Fig 4). The studies presented few biases, especially regarding the methods used for identification of the outcomes, being mostly high quality. Among the strengths, adequate sample size and its relationship with the analyses conducted were prominent.

Based on these findings, a sensitivity analysis was performed. Studies that received, at least, one response 'No' on any item were excluded. Accordingly, case-control studies, which have the lowest level of evidence among the selected study types, were also excluded as previously proposed in the protocol. Finally, studies with outlier incidences were identified for exclusion.


Despite the variability found among the studies, we observed consistent results considering the performed for each step of sensitivity analysis, which highlight the robustness of our findings, with outlier analysis being conducted. The summary of sensitivity analysis can be seen in Table 3. (S2 Forest and funnel plots of venous thromboembolism and bleeding according sensitivity analysis, and 95%CI graph for sensitivity analysis groups (S2A Fig).

Discussion


We found a pooled incidence of 13.68% and 11.60% for VTE and bleeding, respectively, in adults with malignant CNS neoplasm. The occurrence of VTE in the first six months post-diagnosis is up to 7-fold higher in patients with brain tumors [51]. Previous systematic reviews already investigated the relationship between cancer and having a VTE. The majority of them assessed the risk for these events and commonly included several types and sites of cancer,




(2A) Forest plot of incidence and 95% confidence interval of venous thromboembolism in overall patients with malignant CNS neoplasm.



(2C) Forest plot of incidence and 95% confidence interval of venous thromboembolism in a subgroup of patients diagnosed with GBM.



(2B) Forest plot of incidence and 95% confidence interval of bleeding in overall patients with malignant CNS neoplasm.




(2D) Forest plot of incidence and 95% confidence interval of bleeding in a subgroup of patients diagnosed with GBM.


Fig 2. Forest plots of pooled incidence and 95% confidence interval of venous thromboembolism and bleeding in patients with overall malignant primary CNS neoplasm and GBM subgroup. (2A) Forest plot of incidence and 95% confidence interval of venous thromboembolism in overall patients with malignant CNS neoplasm; (2B) Forest plot of incidence and 95% confidence interval of bleeding in overall patients with malignant CNS neoplasm; (2C) Forest plot of incidence and 95% confidence interval of venous thromboembolism in a subgroup of patients diagnosed with GBM; (2D) Forest plot of incidence and 95% confidence interval of bleeding in a subgroup of patients diagnosed with GBM.

<https://doi.org/10.1371/journal.pone.0304682.g002>


regardless of being benign or malignant, recurrent or metastatic [51–53]. Qian et al. [53] analyzed nine studies and showed that brain tumors, especially those diagnosed with HGG and GBM and submitted to neurosurgery, are associated with an increased risk of VTE. However,




(3A) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for venous thromboembolism in overall patients with CNS malignant neoplasm.



(3C) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for venous thromboembolism in patients with diagnosed GBM.




(3B) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for bleeding in overall patients with CNS malignant neoplasm.




(3D) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for bleeding in patients with diagnosed GBM.

Fig 3. Funnel plots analysis of venous thromboembolism and bleeding in patients with overall malignant primary CNS neoplasm and GBM subgroup. (3A) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for venous thromboembolism in overall patients with CNS malignant neoplasm; (3B) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for bleeding in overall patients with CNS malignant neoplasm; (3C) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for venous thromboembolism in patients with diagnosed GBM; (3D) Funnel plot of Freeman-Tukey Double Arcsine Transformed Proportion using the random effects model for bleeding in patients with diagnosed GBM.

<https://doi.org/10.1371/journal.pone.0304682.g003>



(A) Traffic-light plot of risk of bias assessment per study.



(B) Summary plot of risk of bias assessment. Item 9 (i.e., Was the response rate adequate, and if not, was the low response rate managed appropriately?) was considered not applicable.

Fig 4. Risk of bias assessment. (A) Traffic-light plot of risk of bias assessment per study. (B) Summary plot of risk of bias assessment. Item 9 (i.e., Was the response rate adequate, and if not, was the low response rate managed appropriately?) was considered not applicable.

<https://doi.org/10.1371/journal.pone.0304682.g004>

the authors did not mention the prevalence of VTE among these patients [52]. Horsted, West and Grainge [54] pointed out that having brain cancer lead to the second highest risk of VTE inferior only to pancreas cancer. When considering prevalence data, Sun et al. [52] found a prevalence of 7% of VTE in cancer patients undergoing chemotherapy, but only eight among the 102 studies were conducted with brain cancer patients. Regarding brain cancer, the prevalence was ranged between 4 and 5% with low heterogeneity, including five studies with patients diagnosed with recurrent gliomas [52]. Other systematic reviews had effectiveness and safety of prophylaxis and/or treatment for reducing VTE and its complications as purpose

Table 3. Summary of venous thromboembolism and bleeding incidence according to each step of sensitivity analysis.

	Original		High quality studies		Without outliers	
	Pooled Incidence (95%CI)	I ²	Pooled Incidence (95%CI)	I ²	Pooled Incidence (95%CI)	I ²
CNS						
VTE	13.68 (9.79;18.09)	99%	11.72 (8.33;15.59) (S2b Fig in S1 File)	98%	18.25 (14.95;21.79) (S2e Fig in S1 File)	92%
Bleeding	11.60 (6.16;18.41)	97%	7.57 (4.08;11.97) (S2c Fig in S1 File)	95%	28.42 (23.58;33.51) (S2f Fig in S1 File)	0%
GBM						
VTE	16.10 (10.52;22.57)	98%	13.15 (8.51;18.59) (S2d Fig in S1 File)	97%	20.41 (14.79;26.66) (S2g Fig in S1 File)	95%
Bleeding	8.29 (3.26; 15.24)	95%	NA	NA	3.88 (2.96;4.92) (S2h Fig in S1 File)	50%

CNS: Central Nervous System; CI: Confidence interval; GBM: Glioblastoma Multiforme; VTE: Venous Thromboembolism.

<https://doi.org/10.1371/journal.pone.0304682.t003>

[48, 55–59]. For bleeding, we observed similar publications that focused on risk of bleeding when submitting patients to a thromboprophylaxis [60]. Accordingly, this is the first systematic review and meta-analysis that provided incidence of both VTE and bleeding in adults with malignant CNS neoplasm.

In the present study, the pooled incidence of VTE was similar to values previously reported [54]. It is worth noting that the comparison of our pooled incidence with those found for Horsted, West and Grainge [54] is limited due to their methodological choice for dividing the studies based on average and high risk. When considering the value found by Sun et al. [52], we must analyze this difference cautiously. Despite their description as brain tumor, most studies were based on recurrent gliomas, especially GBM. Stage of cancer, recurrence, metastasis, and neurosurgery may also play a role in incidence of VTE. This finding may be attributed to the shorter exposure time of these patients to the risk of a VTE. Kaptein et al. [27] showed that the median recurrence among GBM was nearly 8 months, varying between 4.8 months and one year. In newly diagnosed HGG patients, Thaler et al. [61] showed that the probability of having a VTE ranged between 3.3 and almost 40% when considering cancer-related factors (e.g., leukocyte and platelet count, P-selectin, prothrombin-fragment 1 + 2, FVIII activity, and D-dimer).

For GBM, the pooled incidence of VTE was higher than that of overall CNS malignant neoplasms. Due to the hypercoagulability induced by the malignancy, intravascular thrombosis is more frequently observed in GBM cases when compared to other malignant CNS tumors [62]. Conventional treatment stages (e.g., tumor resection, chemotherapy, and radiotherapy) can be considered risk factors for both VTE and bleeding [9, 30, 63]. These factors may contribute to the greater incidence in patients with GBM.

In addition, the risk for VTE is higher in the first two months after surgery in GBM patients [64]. During the first month, the incidence may reach up to 47%, within the period immediately after surgery, it is 40% [64]. Pulmonary embolism was observed in 60% of the cases, with 13% mortality [64]. Patients with GBM are included in the three groups with the highest risk of thromboembolic complications, in addition to those with pancreas, liver and ovarian cancer [65, 66].

Although the incidence of malignant CNS tumors is higher in men [67], the incidence of VTE and bleeding was similar when considering the subgroup analysis, corroborating previous investigations [31, 32, 68]. Mulder et al. [69] assessed the occurrence of VTE in the first six months of the follow-up and found no difference between the sexes in sub-distribution hazard ratios (SHR = 1.02; 0.98–1.07). The cumulative incidence was 1.61 (95%CI 1.56–1.66) in

women and 1.78 (95%CI 1.73–1.83) in men. This may be attributed to the severity of the disease, which exposes both sexes to similar risk factors.

In this systematic review and meta-analysis, the highest incidence of VTE and/or bleeding was observed in older adults (≥ 60 years). Aging may increase the risk of VTE. In patients with cancer, the occurrence of VTE can increase by up to 3 times when compared to their younger counterparts [70, 71]. In a population-based case-control study of older adults with different types of cancer, the likelihood of thrombotic events increased between 27 and 92% [72]. In a cohort study involving patients with and without cancer, who suffered from VTE, fatal bleeding occurred in 0.8% of the older adults and 0.4% of their younger counterparts, resulting in an HR equal to 2.0 (95% CI = 1.2–3.4) [73]. Regardless of cancer type, aging is associated with an increased risk of thrombosis, particularly due to reduced physical activity, a decline in mobility, greater disability in activities of daily living and systemic activation of coagulation.

Asian and European countries present a greater incidence and health disorders caused by CNS tumors [4], which may explain the larger number of studies from these regions. The age-related incidence is greater in North American and European countries [4], which also agree with our findings. Incidence according to socioeconomic subgroup based on World Banking classification differed between high-income and upper-middle income countries. Despite being considered a health problem, especially in high-income countries, the lack of an opportune and accurate diagnosis of CNS neoplasm in low-income regions may explain the lower incidence rates and, consequently, result in less access to treatment and higher disability and mortality [4]. Thus, the absence of studies from low and lower-middle income countries could also justify these findings. Moreover, cancer-related risk factors for VTE include brain cancer (as a high risk for developing VTE), as well as stage of cancer, especially advanced stage, and active treatment, while being older with black ethnicity and presence of comorbidities are patient-related risk factors [74]. Briefly, these patient-related factors are often found among low and lower-middle income households and linked with over 80% of premature deaths [75], which can be even more alarming when considering the lack of data for these populations. However, the healthcare access is limited and commonly associated with ageing in a context of poverty and income inequality [76].

This systematic review and meta-analysis presented limitations and strengths. Despite the studies included, the lack of detailed sample descriptions hampered subgroup analyses for both sociodemographic variables and those related to CNS neoplasm. Moreover, although the studies were cohorts, the retrospective design predominated, and cohort and case-control nested studies were included, which may be due to the less detailed sample descriptions and treatments. It is worth nothing that the studies often presented the events according to the total sample, which, at times, consisted of more than one age range, both sexes and different types of CNS tumors.

Among the strengths are the comprehensive search strategy and the adoption of highly inclusive eligibility criteria, which provided a general overview of the literature. We also carried out a sensitivity analysis and apply an instrument to assess methodological quality and risk of bias as recommended. Sensitivity analyses followed two distinct patterns. Outlier exclusion was guided by a methodological rationale, specifically targeting studies where the event incidence was 1.5 times greater than the interquartile range. This analysis demonstrated a pooled incidence rate of VTE in GBM tumors consistent with that reported in the literature (20.41%) [9]. The second approach involved subgroup analysis, categorizing groups based on demographic variables (such as sex and age) and tumor type. In the studies reviewed, older age emerged as the primary variable identified as a risk factor for both VTE outcomes and bleeding. Performance status was an independent risk factor in three articles, albeit with variations

in instruments and data collection methodologies. Nevertheless, it was noted that several studies lacked multivariate analyses, either due to the lack of significance in univariate analysis, the size of sample subgroups, or the specific objective of investigating a particular tumor marker.

The substantial heterogeneity observed should be analyzed with caution. A high I^2 is expected due to the study design (i.e., meta-analysis of incidence) and does not necessarily imply either relevant heterogeneity or the absence of a conclusion [77]. The interstudy variability may be attributed to the lack of standardized data collection and registration, types of malignant tumors and diagnostic methods, especially in asymptomatic cases, cancer stage, type of treatment, the introduction of thromboprophylaxis and other patient-related factors. In addition, it is important to consider different concepts for defining bleeding and its prognosis [77], particularly in postoperative cases. For instance, we were unable to analyze whether most cases actually involved major bleeding (i.e., clinically overt bleeding), clinically relevant non-major bleeding (i.e., episode associated with medical intervention that did not meet the criteria for major bleeding, which can affect treatment continuation and compromise patients' activities of daily living) or minor bleeding potentially misclassified since the amount of bleeding and site can influence the clinical outcome (serious/disabling, severe and life-threatening) [78].

The findings suggest gaps in the literature regarding the influence of tumor type and characteristics on the incidence of events of interest, especially investigating possible confounders and biases, for instance, the characteristics inherent to surgical procedures (type of procedure, duration, presence and volume of bleeding, pre, peri- and/or post-operative, prophylactic measures, possible complications, among others), active cancer treatment (radiotherapy and separate or concomitant chemotherapy) and health history (including mapping comorbidities). Future perspectives indicate the need for scientific knowledge on the topic in low-income countries with greater social inequality, making it possible to obtain incidence data in these regions, thereby favoring greater understanding of the role of the social determinants of health.

Conclusion

According to this research, the pooled incidence showed variability across all analyses and their subgroups for both events. Subgroup analysis showed that being older than 60 years or having GBM diagnosis presented higher pooled incidence values in comparison to overall CNS malignant neoplasm. In addition to the sensitivity analysis, when considering the outlier criterion, it's noted a higher pooled incidence among GBM, mirroring findings in the literature. Further studies from low and lower-middle income countries should be encouraged.

Supporting information

S1 Appendix. REDCap file for data extraction.

(DOCX)

S2 Appendix. Guidance for screening and data extraction.

(DOCX)

S1 Checklist.

(DOCX)

S1 File. Forest and funnel plots of venous thromboembolism and bleeding according sensitivity analysis, and 95%CI graph to sensitivity analysis groups.

(ZIP)

S2 File. a-f. Forest plots of venous thromboembolism and bleeding according subgroup analysis.
(ZIP)

S1 Table. Search strategy according to electronic databases.
(DOCX)

S2 Table. Characteristics of excluded studies (*ordered by study ID*).
(DOCX)

S3 Table. Conflict of interest and funding reported in the included studies.
(DOCX)

Acknowledgments

The authors are grateful to Brazilian Ministry of Health for their support. We also would like to thank all the other researchers who are part of the TROMBOGLIO Study Group (i.e., Ana Carolina Sigolo Levy, Silvana Soares dos Santos, Sabrina Dos Santos Pinho Costa, Jessica Carolina Andrade dos Santos, Carolina Fittipaldi Pessoa, Daniela Galvão Barros de Oliveira, Thiago Santos Vieira, Danielli de Almeida Matias, Kleyton Medeiros, Alessandra Buccaran, Breno Gray Milano, Raiane Alves da Costa, and Fabiana Spillari Viola).

Author Contributions

Conceptualization: Viviane Cordeiro Veiga, Flavia Regina Moraes, Talita Rantin Belucci, Camilla Akemi Felizardo Yamada.

Data curation: Viviane Cordeiro Veiga, Stela Verzinhasse Peres, Thatiane L. V. D. P. Ostolin, Flavia Regina Moraes, Camilla Akemi Felizardo Yamada.

Formal analysis: Stela Verzinhasse Peres, Thatiane L. V. D. P. Ostolin.

Funding acquisition: Viviane Cordeiro Veiga, Flavia Regina Moraes.

Investigation: Stela Verzinhasse Peres, Thatiane L. V. D. P. Ostolin.

Methodology: Stela Verzinhasse Peres, Thatiane L. V. D. P. Ostolin.

Project administration: Flavia Regina Moraes.

Resources: Viviane Cordeiro Veiga, Flavia Regina Moraes, Camilla Akemi Felizardo Yamada.

Software: Stela Verzinhasse Peres, Thatiane L. V. D. P. Ostolin.

Supervision: Viviane Cordeiro Veiga, Flavia Regina Moraes.

Validation: Viviane Cordeiro Veiga, Flavia Regina Moraes, Camilla Akemi Felizardo Yamada.

Visualization: Viviane Cordeiro Veiga.

Writing – original draft: Stela Verzinhasse Peres, Thatiane L. V. D. P. Ostolin.

Writing – review & editing: Viviane Cordeiro Veiga, Stela Verzinhasse Peres, Thatiane L. V. D. P. Ostolin, Flavia Regina Moraes, Talita Rantin Belucci, Carlos Afonso Clara, Alexandre Biasi Cavalcanti, Feres Eduardo Aparecido Chaddad-Neto, Gabriel N. de Rezende Batistella, Iuri Santana Neville, Alex M. Baeta, Camilla Akemi Felizardo Yamada.

References

1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017.

- Neuro Oncol. 2020 Oct 1. 22(12 Suppl 2):iv1–iv96. <https://doi.org/10.1093/neuonc/noaa200> PMID: 33123732
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021 May 1. 71(3):209–49. <https://doi.org/10.3322/caac.21660> PMID: 33538338
 3. Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. *JAMA*. 2023 Feb 21. 329(7):574–87. <https://doi.org/10.1001/jama.2023.0023> PMID: 36809318
 4. Fan Y, Zhang X, Gao C, Jiang S, Wu H, Liu Z, et al. Burden and trends of brain and central nervous system cancer from 1990 to 2019 at the global, regional, and country levels. *Archives of Public Health*. 2022 Dec 180(1):1–14. <https://doi.org/10.1186/s13690-022-00965-5> PMID: 36115969
 5. Parkin DM, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. *Cancer Epidemiol Biomarkers Prev*. 2014 Jun 2. 23(6):953–66. <https://doi.org/10.1158/1055-9965.EPI-14-0281> PMID: 24700176
 6. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018 Nov 14. 68(6):394–424. <https://doi.org/10.3322/caac.21492> PMID: 30207593
 7. Mulder FI, Bosch FTM, Young AM, Marshall A, McBane RD, Zemla TJ, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. *Blood*. 2020 Sep 17. 136(12):1433–41. <https://doi.org/10.1182/blood.2020005819> PMID: 32396939
 8. Horsted F, West J, Grainge MJ. Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. *PLoS Med*. 2012 Jul 31. 9(7). <https://doi.org/10.1371/journal.pmed.1001275> PMID: 22859911
 9. Jo J, Diaz M, Horbinski C, Mackman N, Bagley S, Broekman M, et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. *Neuro Oncol*. 2023 Apr 26. 25(8): 1381–1394. <https://doi.org/10.1093/neuonc/noad059> PMID: 37100086
 10. Lyman GH, Carrier M, Ay C, Nisio M Di, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. *Blood Adv*. 2021 Feb 23. 5(4):927–74. <https://doi.org/10.1182/bloodadvances.2020003442> PMID: 33570602
 11. Nyquist P, Bautista C, Jichici D, Burns J, Chhangani S, DeFilippis M, et al. Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Evidence-Based Guideline: A Statement for Healthcare Professionals from the Neurocritical Care Society. *Neurocrit Care*. 2016 Feb 1. 24(1):47–60. <https://doi.org/10.1007/s12028-015-0221-y> PMID: 26646118
 12. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Chapter 5: Systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z (Editors). *JBRI Reviewer's Manual*. JBI, 2017. Available from: <https://reviewersmanual.joannabriggs.org/>
 13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29. 372:n71. <https://doi.org/10.1136/bmj.n71> PMID: 33782057
 14. Schulman S, Anger SU, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. *Journal of Thrombosis and Haemostasis*. 2010 Jan 1. 8(1):202–4. <https://doi.org/10.1111/j.1538-7836.2009.03678.x> PMID: 19878532
 15. Auer TA, Renovanz M, Marini F, Brockmann MA, Tanyildizi Y. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab. *J Neurooncol*. 2017 May 29. 133(3):571–9. <https://doi.org/10.1007/s11060-017-2467-z> PMID: 28555422
 16. Barbaro M, Blinderman CD, Iwamoto FM, Kreisl TN, Welch MR, Odia Y, et al. Causes of Death and End-of-Life Care in Patients with Intracranial High-Grade Gliomas: A Retrospective Observational Study. *Neurology*. 2022 Jan 18. 98(3):E260–6. <https://doi.org/10.1212/WNL.0000000000013057> PMID: 34795049
 17. Bruhns RP, James WS, Torabi M, Borgstrom M, Roussas A, Lemole M. Survival as a Function of Non-steroidal Anti-inflammatory Drug Use in Patients with Glioblastoma. *Cureus*. 2018 Sep 10. 10(9): e3277. <https://doi.org/10.7759/cureus.3277> PMID: 30443448
 18. Carney BJ, Uhlmann EJ, Puligandla M, Mantia C, Weber GM, Neuberg DS, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. *Journal of Thrombosis and Haemostasis*. 2019 Jan 1. 17(1):72–6. <https://doi.org/10.1111/jth.14336> PMID: 30450803
 19. Diaz M, Jo J, Smolkin M, Ratcliffe SJ, Schiff D. Risk of Venous Thromboembolism in Grade II–IV Gliomas as a Function of Molecular Subtype. *Neurology*. 2021 Feb 16. 96(7):E1063–9. <https://doi.org/10.1212/WNL.0000000000011414> PMID: 33361259

20. Ebeling M, Lüdemann W, Frisius J, Karst M, Schedel I, Gerganov V, et al. Venous thromboembolic complications with and without intermittent intraoperative and postoperative pneumatic compression in patients with glioblastoma multiforme using intraoperative magnetic resonance imaging. A retrospective study. *Neurochirurgie*. 2018 May 30. 64(3):161–5. <https://doi.org/10.1016/j.neuchi.2018.04.007> PMID: 29859696
21. Eisele A, Seystahl K, Rushing EJ, Roth P, Le Rhun E, Weller M, et al. Venous thromboembolic events in glioblastoma patients: An epidemiological study. *Eur J Neurol*. 2022 May 12. 29(8):2386–97. <https://doi.org/10.1111/ene.15404> PMID: 35545894
22. Ening G, Osterheld F, Capper D, Schmieder K, Brenke C. Risk factors for glioblastoma therapy associated complications. *Clin Neurol Neurosurg*. 2015 Jan 9. 134:55–9. <https://doi.org/10.1016/j.clineuro.2015.01.006> PMID: 25942630
23. Fisher JL, Palmisano S, Schwartzbaum JA, Svensson T, Lönn S. Comorbid conditions associated with glioblastoma. *J Neurooncol*. 2014 Jan 11. 116(3):585–91. <https://doi.org/10.1007/s11060-013-1341-x> PMID: 24414135
24. Helmi A, Chan A, Towfighi S, Kapadia A, Perry J, Ironside S, et al. Incidence of Dural Venous Sinus Thrombosis in Patients with Glioblastoma and Its Implications. *World Neurosurg*. 2019 May 1. 25: e189–97. <https://doi.org/10.1016/j.wneu.2019.01.039> PMID: 30684707
25. Huang Y, Ding H, Luo M, Li S, Xie C, Zhong Y, et al. Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma. *Supportive Care in Cancer*. 2022 Apr 13. 30(7):6063–9. <https://doi.org/10.1007/s00520-022-07050-1> PMID: 35419733
26. Jo J, Donahue J, Sarai G, Petroni G, Schiff D. Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk? *Neuro Oncol*. 2022 Aug 12. 24(3):455–64. <https://doi.org/10.1093/neuonc/noab198> PMID: 34383073
27. Kaptein FHJ, Stals MAM, Kapteijn MY, Cannegieter SC, Dirven L, van Duinen SG, et al. Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. *Journal of Thrombosis and Haemostasis*. 2022 May 9. 20(7):1665–73. <https://doi.org/10.1111/jth.15739> PMID: 35460331
28. Kaye B, Ali A, Correa Bastianon Santiago RA, Ibrahim B, Isidor J, Awad H, et al. The Role of EGFR Amplification in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma. *Current Oncology*. 2023 May 12. 30(5):4946–56. <https://doi.org/10.3390/curroncol30050373> PMID: 37232831
29. Khoury MN, Missios S, Edwin N, Sakruti S, Barnett G, Stevens G, et al. Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. *Neurooncol Pract*. 2016 Jun 25. 3(2):87–96. <https://doi.org/10.1093/nop/npv028> PMID: 31386010
30. Lee YP, Jung HA, Lee MS, Choi JW, Kong DS, Seol HJ, et al. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma. *J Neurooncol*. 2022 Feb 1. 156(3):541–9. <https://doi.org/10.1007/s11060-021-03930-4> PMID: 35094201
31. Lee I, Adimadhyam S, Nutescu EA, Zhou J, Asfaw AA, Sweiss KI, et al. Arterial and venous thromboembolic safety of bevacizumab in patients with high-grade gliomas. *Pharmacotherapy*. 2019 Sep 1. 39(9):921. <https://doi.org/10.1002/phar.2310>
32. Lim G, Ho C, Roldan Urgoti G, Leugner D, Easaw J. Risk of Venous Thromboembolism in Glioblastoma Patients. *Cureus*. 2018 May 23; 10(5):e2678. <https://doi.org/10.7759/cureus.2678> PMID: 30050733
33. Liu X, Zhang X, Ma T, Li M, Zhang L, Li S, et al. Risk factors for postoperative thrombosis-related complications in patients undergoing malignant brain tumor resection: a retrospective cohort study. *Front Neurol*. 2023 Apr 18. 14: 1108596. <https://doi.org/10.3389/fneur.2023.1108596> PMID: 37144008
34. Liu W, Qdaisat A, Yeung J, Lopez G, Weinberg J, Zhou S, et al. The Association Between Common Clinical Characteristics and Postoperative Morbidity and Overall Survival in Patients with Glioblastoma. *Oncologist*. 2019 Apr 1. 24(4):529–36. <https://doi.org/10.1634/theoncologist.2018-0056> PMID: 30049883
35. Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberger D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. *Blood*. 2017 Jun 22. 129(25):3379–85. <https://doi.org/10.1182/blood-2017-02-767285> PMID: 28468796
36. McGahan BG, Neilsen BK, Kelly DL, McComb RD, Kazmi SAJ, White ML, et al. Assessment of vascularity in glioblastoma and its implications on patient outcomes. *J Neurooncol*. 2017 Mar 1. 132(1):35–44. <https://doi.org/10.1007/s11060-016-2350-3> PMID: 28102487
37. Missios S, Kalakoti P, Nanda A, Bekelis K. Craniotomy for Glioma Resection: A Predictive Model. *World Neurosurg*. 2015 Jun 1. 83(6):957–64. <https://doi.org/10.1016/j.wneu.2015.04.052> PMID: 25943986
38. Rahman R, Catalano PJ, Reardon DA, Norden AD, Wen PY, Lee EQ, et al. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. *J Neurooncol*. 2015 Aug 23. 124(1):137–46. <https://doi.org/10.1007/s11060-015-1820-3> PMID: 26033544

39. Nakano F, Matsubara T, Ishigaki T, Hatazaki S, Mouri G, Nakatsuka Y, et al. Incidence and risk factor of deep venous thrombosis in patients undergoing craniotomy for brain tumors: A Japanese single-center, retrospective study. *Thromb Res*. 2018 May 1; 165:95–100. <https://doi.org/10.1016/j.thromres.2018.03.016> PMID: 29605752
40. Park AK, Waheed A, Forst DA, Al-Samkari H. Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies. *Neuro Oncol*. 2022 Jun 1; 24(6):964–73. <https://doi.org/10.1093/neuonc/noab240> PMID: 34647594
41. Mir Seyed Nazari P, Berghoff AS, Preusser M, Moik F, Posch F, Ricken G, et al. Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. *ESMO Open*. 2020 May 17; 5(3):e000647. <https://doi.org/10.1136/esmoopen-2019-000647> PMID: 32424065
42. Rinaldo L, Brown DA, Bhargav AG, Rusheen AE, Naylor RM, Gilder HE, et al. Venous thromboembolic events in patients undergoing craniotomy for tumor resection: Incidence, predictors, and review of literature. *J Neurosurg*. 2020; 132(1):10–21. <https://doi.org/10.3171/2018.7.JNS181175>
43. Seidel C, Hentschel B, Simon M, Schnell O, Heese O, Tatagiba M, et al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. *J Neurol*. 2013 Mar; 260(3):847–55. <https://doi.org/10.1007/s00415-012-6718-9> PMID: 23104124
44. Senders JT, Snijders TJ, van Essen M, van Bentum GM, Seute T, de Vos FY, et al. Length of Thromboprophylaxis in Patients Operated on for a High-Grade Glioma: A Retrospective Study. *World Neurosurg*. 2018 Jul 1; 115:e723–30. <https://doi.org/10.1016/j.wneu.2018.04.151> PMID: 29715571
45. Shi S, Cheng J, Chen H, Zhang Y, Zhao Y, Wang B. Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study. *Thromb Res*. 2020 Dec 1; 196:245–50. <https://doi.org/10.1016/j.thromres.2020.09.005> PMID: 32919179
46. Streiff MB, Ye X, Kickler TS, Desideri S, Jani J, Fisher J, et al. A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors. *J Neurooncol*. 2015 Sep 29; 124(2):299–305. <https://doi.org/10.1007/s11060-015-1840-z> PMID: 26100546
47. Thaler J, Preusser M, Ay C, Kaider A, Marosi C, Zielinski C, et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. *Thromb Res*. 2013 Feb; 131(2):162–5. <https://doi.org/10.1016/j.thromres.2012.09.020> PMID: 23084660
48. Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, et al. Mutant IDH1 and thrombosis in gliomas. *Acta Neuropathol*. 2016 Dec 1; 132(6):917–30. <https://doi.org/10.1007/s00401-016-1620-7> PMID: 27664011
49. Zhou Q, Ke X, Xue C, Li S, Huang X, Zhang B, et al. A Nomogram for Predicting Early Recurrence in Patients with High-Grade Gliomas. *World Neurosurg*. 2022 Aug 1; 164:e619–28. <https://doi.org/10.1016/j.wneu.2022.05.039> PMID: 35589036
50. Zhang C, Deng Z, Yang Z, Xie J, Hou Z. A nomogram model to predict the acute venous thromboembolism risk after surgery in patients with glioma. *Thromb Res*. 2023 Apr; 224:21–31. <https://doi.org/10.1016/j.thromres.2023.02.002> PMID: 36805800
51. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. *Blood*. 2021 Apr 8; 137(14):1959–69. <https://doi.org/10.1182/blood.2020007338> PMID: 33171494
52. Sun MY, Bhaskar SMM. Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis. *Diagnostics (Basel)*. 2022 Nov; 12(12):2954. <https://doi.org/10.3390/diagnostics12122954> PMID: 36552961
53. Qian C, Yan H, Hu X, Zhang W, Liu H. Increased risk of venous thromboembolism in patients with brain tumors: A systematic review and meta-analysis. *Thromb Res [Internet]*. 2016 Jan; 137:58–63. <https://doi.org/10.1016/j.thromres.2015.11.018> PMID: 26610747
54. Horsted F, West J, Grainge MJ. Risk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. *PLoS Med*. 2012 Jul; 9(7):e1001275. <https://doi.org/10.1371/journal.pmed.1001275> PMID: 22859911
55. Wu S, Lv M, Chen J, Jiang S, Chen M, Fang Z, et al. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis. *Support Care Cancer*. 2022 Dec; 30(12):10407–20; discussion 10416–18. Erratum in: *Support Care Cancer*. 2023 Jun 3;31(6):373. <https://doi.org/10.1007/s00520-022-07433-4> PMID: 36318341
56. Hunter BD, Minichiello T, Bent S. Anticoagulation for the treatment of venous thromboembolism in patients with brain metastases: a meta-analysis and systematic review. *J Thromb Thrombolysis*. 2017 Oct; 44(3):392–8. <https://doi.org/10.1007/s11239-017-1536-7> PMID: 28836150

57. Algattas H, Damania D, DeAndrea-Lazarus I, Kimmell KT, Marko NF, Walter KA, et al. Systematic Review of Safety and Cost-Effectiveness of Venous Thromboembolism Prophylaxis Strategies in Patients Undergoing Craniotomy for Brain Tumor. *Neurosurgery*. 2018 Feb 1; 82(2):142–54. <https://doi.org/10.1093/neuros/nyx156> PMID: 28402497
58. Salmaggi A, Simonetti G, Trevisan E, Beecher D, Carapella CM, Dimeco F, et al. Perioperative thromboprophylaxis in patients with craniotomy for brain tumours: a systematic review. *J Neurooncol*. 2013 Jun; 113(2):293–303. <https://doi.org/10.1007/s11060-013-1115-5> PMID: 23543244
59. Alshehri N, Cote DJ, Hulou MM, Alghamdi A, Alshahrani A, Mekary RA, et al. Venous thromboembolism prophylaxis in brain tumor patients undergoing craniotomy: a meta-analysis. *J Neurooncol*. 2016 Dec; 130(3):561–70. <https://doi.org/10.1007/s11060-016-2259-x> PMID: 27591773
60. Porfidia A, Giordano M, Sturiale CL, D'Arrigo S, Donadini MP, Olivi A, et al. Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis. *Brain Behav*. 2020 Jun; 10(6):e01638. <https://doi.org/10.1002/brb3.1638> PMID: 32314875
61. Thaler J, Ay C, Kaider A, Reitter EM, Haselböck J, Mannhalter C, et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. *Neuro Oncol [Internet]*. 2014 Dec; 16(12):1645–51. <https://doi.org/10.1093/neuonc/nou106> PMID: 24987133
62. Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. *J Thromb Haemost*. 2010 Feb; 8(2):221–7. <https://doi.org/10.1111/j.1538-7836.2009.03690.x> PMID: 19912518
63. Al Megren M, De Wit C, Al Qahtani M, Le Gal G, Carrier M. Management of venous thromboembolism in patients with glioma. *Thromb Res*. 2017 Aug; 156:105–8. <https://doi.org/10.1016/j.thromres.2017.06.010> PMID: 28624717
64. Patel AP, Koltz MT, Sansur CA, Gulati M, Hamilton DK. An analysis of deep vein thrombosis in 1277 consecutive neurosurgical patients undergoing routine weekly ultrasonography. *J Neurosurg*. 2013 Mar; 118(3):505–9. <https://doi.org/10.3171/2012.11.JNS121243> PMID: 23240698
65. Insin P, Vitoopinyoparb K, Thadanipon K, Charakorn C, Attia J, McKay GJ, et al. Prevention of venous thromboembolism in gynecological cancer patients undergoing major abdominopelvic surgery: A systematic review and network meta-analysis. *Gynecol Oncol*. 2021 Apr; 161(1):304–13. <https://doi.org/10.1016/j.ygyno.2021.01.027> PMID: 33563489
66. Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. *J Clin Oncol*. 2011 May 20; 29(15):2099–103. <https://doi.org/10.1200/JCO.2010.32.8294> PMID: 21464402
67. Cancer Today [Internet]. [cited 2023 Sep 21]. Available from: <https://gco.iarc.fr/today/home>
68. Shi S, Cheng J, Zhao Y, Chen W. Incidence, and preoperative and intraoperative prognostic factors of deep venous thrombosis in patients with glioma following craniotomy. *Clin Neurol Neurosurg*. 2021 Nov; 210:106998. <https://doi.org/10.1016/j.clineuro.2021.106998> PMID: 34739883
69. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. *Blood*. 2021 Apr 8; 137(14):1959–69. <https://doi.org/10.1182/blood.2020007338> PMID: 33171494
70. Vergati M, Della-Morte D, Ferroni P, Cereda V, Tosetto L, La Farina F, et al. Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer. *Rejuvenation Res*. 2013 Jun; 16(3):224–31. <https://doi.org/10.1089/rej.2013.1409> PMID: 23521603
71. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. *J Clin Oncol*. 2006 Jan 20; 24(3):484–90. <https://doi.org/10.1200/JCO.2005.03.8877> PMID: 16421425
72. Marks MA, Engels EA. Venous thromboembolism and cancer risk among elderly adults in the United States. *Cancer Epidemiol Biomarkers Prev*. 2014 May; 23(5):774–83. <https://doi.org/10.1158/1055-9965.EPI-13-1138> PMID: 24608188
73. López-Jiménez L, Montero M, González-Fajardo JA, Arcelus JI, Suárez C, Lobo JL et al. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). *Haematologica*. 2006 Aug; 91(8):1046–51. PMID: 16885044
74. Canonico ME, Santoro C, Avvedimento M, Giugliano G, Mandoli GE, Prastaro M, et al. Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment. *Biomolecules*. 2022 Feb 4; 12(2):259. <https://doi.org/10.3390/biom12020259> PMID: 35204760
75. Noncommunicable diseases [Internet]. [cited 2023 Nov 26]. Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>

76. Simões Gaspar R, Rossi L, Hone T, Dornelles AZ. Income inequality and non-communicable disease mortality and morbidity in Brazil States: a longitudinal analysis 2002–2017. *Lancet Reg Health Am*. 2021 Aug 17; 2:100042. <https://doi.org/10.1016/j.lana.2021.100042> PMID: 36779037
77. Franco L, Becattini C, Beyer-Westendorf J, Vanni S, Nitti C, Re R, et al. Definition of major bleeding: Prognostic classification. *Journal of Thrombosis and Haemostasis*. 2020 Nov 1; 18(11):2852–60. <https://doi.org/10.1111/jth.15048> PMID: 32767653
78. Melsen WG, Bootsma MCJ, Rovers MM, Bonten MJM. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. *Clin Microbiol and Infect*. 2014 Feb; 20(2):123–9. <https://doi.org/10.1111/1469-0691.12494> PMID: 24320992